Michael O’Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, shares his thoughts on the current multiple myeloma cellular therapy landscape. He discusses the possible upcoming achievement of FDA approval of CAR T-cell therapy in myeloma, but also the drawbacks with regards to cost and manufacturing difficulties. He thinks that NK cells as an alternative driver for CAR with benefits over T-cells are an exciting development on the horizon in myeloma treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

свернуть